title: Lovastatin alters blood rheology in primary hyperlipoproteinemia: dependence on lipoprotein(a)?
abstract: As part of a randomized, single-blind, comparative study evaluating the efficacy of lovastatin and bezafibrate retard in the treatment of primary hypercholesterolemia, hemorheologic parameters (whole blood viscosity, hematocrit, plasma viscosity, red blood cell aggregation and deformability, and fibrinogen) were studied in 35 patients. Whole blood viscosity and plasma viscosity improved significantly after 3 months of treatment with lovastatin, whereas other hemorheologic variables remained unchanged. Stratifying 24 patients by their lipoprotein Lp(a) levels showed that in those with low Lp(a) (less than or equal to 25 mg/dL) high-density lipoprotein cholesterol increased and red blood cell aggregation as well as deformability decreased considerably, whereas in the group with high Lp(a) levels (greater than 25 mg/dL), the opposite behavior was observed. Treatment of primary hypercholesterolemia with lovastatin may not only reduce the risk for atherosclerotic complications by its pronounced decrease of low-density lipoprotein cholesterol, but also may favorably alter blood rheology, and may decrease insudation of plasmatic components into the arterial wall and improve tissue perfusion, in particular on the microcirculatory level. The possible relevance of Lp(a) levels for the hemorheologic effects of lovastatin remains to be elucidated.
authors.affiliation: Department of Internal Medicine IV, Ulm University Medical Center, Federal Republic of Germany.
authors.forename: W
authors.initials: W
authors.lastname: Koenig
authors.forename: R
authors.initials: R
authors.lastname: Hehr
authors.forename: H H
authors.initials: HH
authors.lastname: Ditschuneit
authors.forename: K
authors.initials: K
authors.lastname: Kuhn
authors.forename: E
authors.initials: E
authors.lastname: Ernst
authors.forename: J
authors.initials: J
authors.lastname: Rosenthal
authors.forename: V
authors.initials: V
authors.lastname: Hombach
mesh_terms: D001629:Bezafibrate / Q000008:administration & dosage / Q000627:therapeutic use; D001809:Blood Viscosity / Q000187:drug effects*; D003692:Delayed-Action Preparations; D004903:Erythrocyte Aggregation / Q000187:drug effects*; D004907:Erythrocyte Deformability / Q000187:drug effects*; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy*; D006951:Hyperlipoproteinemias / Q000097:blood / Q000188:drug therapy*; D008055:Lipids / Q000097:blood; D008074:Lipoproteins / Q000097:blood; D008148:Lovastatin / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D012212:Rheology; D016037:Single-Blind Method
chemical_list: D003692:Delayed-Action Preparations; D008055:Lipids; D008074:Lipoproteins; D008148:Lovastatin; D001629:Bezafibrate